Skip to main content
. 2022 May 25;12:884369. doi: 10.3389/fonc.2022.884369

Table 3.

EVs as biomarkers for the diagnosis of HCC.

Classification Biomarkers Expression Species Type of biological fluid AUROC Clinical significance Refs
m/lEvs AnnexinV+EpCAM+ASPGR1+CD133+taMPs Human serum 0.7439 Diagnosis of HCC/CCA from LC (225)
EpCAM+AnnexinV +ASGPR1+taMPs Human serum 0.7322 Diagnosis of HCC/CCA from LC (225)
Total m/lEVs of peripheral blood Human serum 0.83 Diagnosis of E-HCC from LC (TNM stage I) (226)
sEVs microRNA miR-148a Human serum 0.871 Diagnosis of HCC from NC Diagnosis of E-HCC from LC (227)
0.860
miR-122 Human serum 0.990 Diagnosis of HCC from NC Diagnosis of E-HCC from LC (227)
0.795
miR-1246 Human serum 0.825 Diagnosis of HCC from NC Diagnosis of E-HCC from LC (227)
0.761
miR-638 Human serum —— Associated with tumor recurrence, As a prognostic marker (228)
miR-125b Human serum 0.739 Prediction of recurrence and survival (229)
miR-93 Human serum 0.825 The prognosis and diagnosis of HCC (147)
miR-665 Human, serum —— Diagnosis and prognosis of HCC (230)
Mice
miR-92b Human, serum 0.702 Prediction of E-HCC relapse after LDLT (231)
Rats
miR-21 Human serum —— Detection of E-HCC, Prognostic marker (232)
miR-718 Human serum —— Prediction of HCC relapse after LDLT (233)
miR-21-5p Human serum 0.71 Diagnosis of HCC from LC (234)
miR-21, miR-10b Human, serum —— Prognostic markers of E-HCC (235)
Mice
miR-18a, miR221, miR-222, miR224 Human serum —— Diagnosis of HCC from LC/CHB (223)
miR-101, miR106b, miR-122, miR-195 Human serum —— Diagnosis of HCC from CHB (223)
miR-122, miR148a, miR-1246 Human serum —— Diagnosis of HCC from LC (227)
miRNA-519d, miR-595, miR-939 Human serum —— Diagnosis of HCC from LC (222)
miR-10b-5p, miR-221-3p, miR-223-3p, miR-21-5p Human plasma 0.86 Diagnosis of HCC from CH or LC (234)
lncRNA lncRNA-HEIH Human serum —— Diagnosis of HCV-associated HCC from CHC (236)
LINC02394 Human serum 0.719 Diagnosis of HCC from CHB (237)
LINC00635 Human serum 0.750 Diagnosis of HCC from CHB (237)
LINC00161 Human serum 0.794 Prediction of HCC growth and metastasis (238)
IncRNA-ATB Human serum —— The prognosis of HCC (239)
Lnc85 Human plasma 0.869 Diagnosis of AFP-negative HCC from healthy controls and LC (163)
SENP3-EIF4A1 Human,Mice plasma 0.8028 The diagnosis of HCC (160)
circRNA circFBLIM1 Human,Mice serum —— The therapeutic target of HCC (149)
circ-0051443 Human,Mice plasma 0.8089 The diagnosis and therapeutic target of HCC (161)
circRNA-100338 Human,Mice serum —— The diagnosis and therapeutic target of HCC (240)
circUHRF1 Human,Mice plasma —— The therapeutic target of HCC (169)
circ-DB Human,Mice adipocyte —— The prognosis of HCC (202)
proteins LAPTM4B-35 Human serum —— Prediction of recurrence and diagnosis of HCC (241)
SMAD3 Human,Mice peripheral blood 0.70 The diagnosis of HCC (242)
RAB5A Human serum —— The diagnosis and therapeutic target of HCC (243)
ENO1 Human,Mice serum —— The prognosis of HCC (244)
Other combinations miR-122, miR-148a, AFP Human serum 0.931 Diagnosis of HCC from LC (227)
SMAD3+ATP Human,Mice peripheral blood 0.90 The diagnosis of HCC (242)
lncRNA-RP11-513I15.6, miR-1262/RAB11A Human serum —— Diagnosis of E-HCC from CHB (245)
miRNA-21, lncRNA-ATB Human serum —— The prognosis of HCC, overall survival (239)
ENSG00000258332.1, LINC00635, AFP Human serum 0.894 The diagnosis and prognosis of HCC (237)
AFP、ENST00000248932.1, ENST00000440688.1, ENST00000457302.2 Human plasma 0.905
0.879
Predict the probability of HCC in the cancer‐free groups
Predict the probability of HCC in the CH groups
(246)
Total EVs Total EV Human serum 0.83 Detection of HCC (225)
AFP, GPC3, ALB, APOH, FABP1, FGB, FGG, AHSG, RBP4, TF Human plasma 0.93 Diagnosis of E-HCC from LC (247)
LINC00853 Human serum 0.956 Diagnosis of E-HCC from CH、LC (248)